Active Ingredient

Manufacturing for third parties

DR Healthcare manufactures and markets the active substance (Diamine Oxidase – DAO enzyme) for third parties, both for human and animal use.

We make available to pharmaceutical and food companies that are looking for a reliable supplier, the highest levels of quality, regulatory support and production of Diamine Oxidase, manufactured in our enzyme production plant located in Tarragona (Spain).

The production of this ADI (Active Dietary Ingredient) is vertically integrated so it is able to control the intermediates of its manufacturing.

Customized solutions

DR Healthcare stands out as a leading company in the production of Diamino Oxidasa, which allows us to offer tailored solutions for use in the veterinary, animal health and food sectors.

Our solutions based on Diamino Oxidase are adapted to the new food control standards, which stipulate the control of histamine levels in order to avoid risks of poisoning due to the consumption of large amounts of this biogenic amine present in food.

Veterinary and animal health sector

Veterinary solutions based on Diamino Oxidase for the dietary management of histaminosis and DAO deficiency in domestic animals, livestock and aquaculture. Its health is that of all being vital to control the pathophysiological effects that trigger high levels of histamine.

Food industry sector

FAO and WHO and countries around the world have applied regulations that include the analysis of foods that may contain high levels of histamine and measures to prevent their production through proper conservation, processing and distribution.

Actuality

Press releases and media’s news

New Regulatory Approvals Support DAO Deficiency Solution Expansion

16 March, 2022

In February 2022, the active ingredient diamine oxidase – or DAO – produced by AB Biotek’s DR Healthcare division, as well as the solutions derived from it, have obtained the GRAS (Generally Recognized As Safe, per sections 201(s) and 409 of the U.S. Food & Drug Act) qualification from the U.S. Food & Drug Administration. This allows for the upcoming...

Scientific and clinical evidence in DAO deficiency

Serum Diamine Oxidase Values, Indicating Histamine Intolerance, Influence Lactose Tolerance

12 May, 2022

Download the paper clicking here Abstract: Lactose intolerance (LIT) is one of the major causes of irritable bowel syndrome (IBS) spectrum complaints. Differences in inadequate lactose digestion are described as various LIT phenotypes with basically unknown pathophysiology. In LIT patients, we retrospectively assessed the effect of histamine intolerance (HIT)...

Blog

Not only does the coronavirus alter Christmas

24 December, 2020

The Coronavirus has altered our lives. And it will also alter this Christmas, which will undoubtedly be different. Still, some things are not going to change compared to the Christmas holidays of other years: emotions increase, alcohol is exceeded, meals are exaggerated and, consequently, many people will have heavy digestion, flatulence, a feeling of bloating,...

Activities and events

TRAINING ACTIVITY “DAO DEFICIENCY AND THE ROLE OF THE PHARMACIST IN THE DIAGNOSIS AND TREATMENT”

30 May, 2019

Next Monday 17 June (2019), will take place from 14.00 to 16.00 hours in the University Rovira i Virgili (Edifici N5 Sustainable Chemistry, Assembly Hall.Marcel.li Sunday, 2-4-6, Sescelades Campus 43007-Tarragona, Spain) the training activity “DAO deficiency and the role of the pharmacist in the diagnosis and treatment” (language: Spanish). This training is organized...